Adeniyi Ayinde Abdulwahab
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adeniyi Ayinde Abdulwahab has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Suleiman Danladi
Bayero University Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences Kano,
2 shared publications - Temitope Ibukunoluwa Adegbenro
University of Lagos Faculty of Pharmacy Lagos
2 shared publications - Zainab Iman Sani
Bayero University Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences Kano,
2 shared publications Adedoyin John-Joy Owolade
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile Ife, Osun State, Nigeria
1 shared publicationDamilola Samuel Bodun
Chemoinformatics Academy, Nigeria
1 shared publication- Damilola Samuel Bodun
Department of Biochemistry, Adekunle Ajasin University, Akungba-Akoko, Nigeria
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0352147
Integrated in silico and in vivo larvicidal evaluation of compounds targeting juvenile hormone for malaria vector control
Malaria remains a major global health challenge, particularly in sub-Saharan Africa, where it is a leading cause of morbidity and mortality. Inhibition of the mosquito juvenile hormone binding protein (MJHBP) is essential for developing selective and effective insecticides against malaria vectors. We performed virtual screening on 2,874 compounds from Agrochemical Insecticides Library using Python-based workflow in RDKit and Pandas libraries. The resultant compounds were subjected to molecular docking study against MJHBP (pdb:5V13). Further evaluation was performed through molecular mechanics generalized Born surface area (MM-GBSA) analysis, insecticide-likeness assessment, toxicity and environmental hazard predictions and Density Functional Theory (DFT) studies. The top-ranked compounds, together with the co-crystallized ligand, were subsequently subjected to molecular dynamics (MD) simulations. The molecular docking and MM-GBSA analyses identified fifteen lead compounds as potent inhibitors, exhibiting binding affinities ranging from –49.84 kcal/mol to –89.51 kcal/mol, values comparable to that of the co-crystallized ligand (–75.83 kcal/mol). The DFT results of the analysed compounds indicated that the top candidates, based on docking scores and binding energies, possessed lower HOMO-LUMO energy gap values, 1.52 eV for F3023-0929 and 2.36 eV for F2708-0061, compared to the co-crystallized ligand, which had a gap of 3.43 eV. All the top compounds displayed significant insecticidal potential with minimal environmental hazards. The stability of the most promising compounds (F2708-0061 and F3023-0929), identified based on binding free energy, was further corroborated through MD simulation. Further in vivo experiments revealed that F3023-0929 and F2708-0061 exhibited potent larvicidal activity, with LC₅₀ values of 37.75 ppm and 33.49 ppm, respectively, thereby supporting their potential as promising insecticidal candidates for mosquito control.
- 26 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0352147
Open AccessIntegrated in silico and in vivo larvicidal evaluation of compounds targeting juvenile hormone for malaria vector control
Malaria remains a major global health challenge, particularly in sub-Saharan Africa, where it is a leading cause of morbidity and mortality. Inhibition of the mosquito juvenile hormone binding protein (MJHBP) is essential for developing selective and effective insecticides against malaria vectors. We performed virtual screening on 2,874 compounds from Agrochemical Insecticides Library using Python-based workflow in RDKit and Pandas libraries. The resultant compounds were subjected to molecular docking study against MJHBP (pdb:5V13). Further evaluation was performed through molecular mechanics generalized Born surface area (MM-GBSA) analysis, insecticide-likeness assessment, toxicity and environmental hazard predictions and Density Functional Theory (DFT) studies. The top-ranked compounds, together with the co-crystallized ligand, were subsequently subjected to molecular dynamics (MD) simulations. The molecular docking and MM-GBSA analyses identified fifteen lead compounds as potent inhibitors, exhibiting binding affinities ranging from –49.84 kcal/mol to –89.51 kcal/mol, values comparable to that of the co-crystallized ligand (–75.83 kcal/mol). The DFT results of the analysed compounds indicated that the top candidates, based on docking scores and binding energies, possessed lower HOMO-LUMO energy gap values, 1.52 eV for F3023-0929 and 2.36 eV for F2708-0061, compared to the co-crystallized ligand, which had a gap of 3.43 eV. All the top compounds displayed significant insecticidal potential with minimal environmental hazards. The stability of the most promising compounds (F2708-0061 and F3023-0929), identified based on binding free energy, was further corroborated through MD simulation. Further in vivo experiments revealed that F3023-0929 and F2708-0061 exhibited potent larvicidal activity, with LC₅₀ values of 37.75 ppm and 33.49 ppm, respectively, thereby supporting their potential as promising insecticidal candidates for mosquito control.
- Open Access
- 1 April 2026
- Published by African Field Epidemiology Network in Journal of Interventional Epidemiology and Public Health
- Vol. 9 (Suppl 12)
Structure-based repurposing of antimalarial drugs to inhibit the RNA-dependent RNA polymerase of dengue virus
Introduction: Dengue fever is becoming a global health emergency, being the most widespread mosquito-borne viral disease, putting half the world population at risk of infection. Dengue virus (DENV), the causative agent of the disease, is classified into four serotypes (DENV-1 – DENV-4), each associated with fever and dengue shock syndrome. Currently, no antiviral drugs are approved for the disease; treatments are based on supportive care. This study follows a comprehensive structure-based virtual screening approach to screen a collection of approved antimalarial drugs for binding efficiency and inhibitory potential against DENV RNA-dependent RNA polymerase (DENV RdRp). Method: We retrieved thirty-one (31) approved antimalarial drugs from published literature. This was followed by downloading the three-dimensional structures (3D) of each drug from the PubChem website and the crystal structure of the protein (PDB ID: 2J7W) from the Protein Data Bank. We computed the root mean square deviation (RMSD) to validate the docking study. The molecular docking and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) evaluation were performed using the Maestro Schrodinger software user interface. The Maestro’s molecular visualisation tool was utilised to perform a post-docking analysis for each of the top drug candidates Result: The computed RMSD for the redocked cocrystallized ligand was 2.0 Å. The docking scores for the top 5 drug candidates were Chloroquine (-4.109 kcal/mol), 3-hydroxyquinine (-4.01 kcal/mol), Tetracycline (-6.494 kcal/mol), Artesunate (-4.4 kcal/mol) and Chlorproguanil (-4.021 kcal/mol). The MMGBSA (dG bind) for the top five drug candidates were Chloroquine (-40.66 kcal/mol), 3-hydroxyquinine (-36.95 kcal/mol), Tetracycline (-36.69 kcal/mol), Artesunate (-35.17 kcal/mol), and Chlorproguanil (-34.18 kcal/mol). The post-docking analysis revealed considerable intermolecular interactions between the drug candidates and protein. Conclusion: Several clinically approved antimalarial agents, including chloroquine, 3-hydroxyquinine, tetracycline, and artesunate, demonstrated favourable binding affinities and stable interactions with catalytically essential residues of the enzyme (DENV RdRp). These interactions suggest potential inhibitory effects on viral replication consistent with previous in vitro and in vivo observations. Future studies should integrate molecular dynamics simulations, enzymatic inhibition assays, and animal model testing to confirm their antiviral efficacy and clarify the molecular basis of NS5 inhibition.
- 1 April 2026
- Published by African Field Epidemiology Network in Journal of Interventional Epidemiology and Public Health
- Vol. 9 (Suppl 12)
Open AccessStructure-based repurposing of antimalarial drugs to inhibit the RNA-dependent RNA polymerase of dengue virus
Introduction: Dengue fever is becoming a global health emergency, being the most widespread mosquito-borne viral disease, putting half the world population at risk of infection. Dengue virus (DENV), the causative agent of the disease, is classified into four serotypes (DENV-1 – DENV-4), each associated with fever and dengue shock syndrome. Currently, no antiviral drugs are approved for the disease; treatments are based on supportive care. This study follows a comprehensive structure-based virtual screening approach to screen a collection of approved antimalarial drugs for binding efficiency and inhibitory potential against DENV RNA-dependent RNA polymerase (DENV RdRp). Method: We retrieved thirty-one (31) approved antimalarial drugs from published literature. This was followed by downloading the three-dimensional structures (3D) of each drug from the PubChem website and the crystal structure of the protein (PDB ID: 2J7W) from the Protein Data Bank. We computed the root mean square deviation (RMSD) to validate the docking study. The molecular docking and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) evaluation were performed using the Maestro Schrodinger software user interface. The Maestro’s molecular visualisation tool was utilised to perform a post-docking analysis for each of the top drug candidates Result: The computed RMSD for the redocked cocrystallized ligand was 2.0 Å. The docking scores for the top 5 drug candidates were Chloroquine (-4.109 kcal/mol), 3-hydroxyquinine (-4.01 kcal/mol), Tetracycline (-6.494 kcal/mol), Artesunate (-4.4 kcal/mol) and Chlorproguanil (-4.021 kcal/mol). The MMGBSA (dG bind) for the top five drug candidates were Chloroquine (-40.66 kcal/mol), 3-hydroxyquinine (-36.95 kcal/mol), Tetracycline (-36.69 kcal/mol), Artesunate (-35.17 kcal/mol), and Chlorproguanil (-34.18 kcal/mol). The post-docking analysis revealed considerable intermolecular interactions between the drug candidates and protein. Conclusion: Several clinically approved antimalarial agents, including chloroquine, 3-hydroxyquinine, tetracycline, and artesunate, demonstrated favourable binding affinities and stable interactions with catalytically essential residues of the enzyme (DENV RdRp). These interactions suggest potential inhibitory effects on viral replication consistent with previous in vitro and in vivo observations. Future studies should integrate molecular dynamics simulations, enzymatic inhibition assays, and animal model testing to confirm their antiviral efficacy and clarify the molecular basis of NS5 inhibition.
- Open Access
- 12 November 2025
- Published by Oxford University Press (OUP) in Biology Methods and Protocols
- Vol. 10 (1)
In-silico Identification of Phytochemical Compounds from Various Medicinal Plants as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors Utilizing Molecular Docking and Molecular Dynamics Simulations
HIV is a global public health challenge. The Reverse Transcriptase (RT) enzyme facilitates an important step in HIV replication. Inhibition of this enzyme provides a critical target for HIV treatment. The aim of this study is to employ computational techniques to screen bioactive compounds from different medicinal plants towards identifying potent HIV-1 RT inhibitors better activity than the current ones. We conducted a literature review of HIV-1 RT inhibitors, and eighty-four (84) compounds, while target receptor (1REV) was retrieved from Protein Data Bank. The molecular docking and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) evaluations were performed using the Maestro Schrodinger software user interface. The drug-likeness and pharmacokinetic profile evaluation were carried out using SwissADME and ADMETlab3.0 web servers. Lastly, molecular dynamics simulation study was conducted using the Desmond tool of Schrodinger. The molecular docking study revealed that Rosmarinic acid (-13.265 kcal/mol), Evafirenz/standard drug (-12.175 kcal/mol), Arctigenin (-11.322 kcal/mol), Luteolin (-11.274 kcal/mol), Anolignan A (-11.157 kcal/mol) and Quercetin (-11.129 kcal/mol) can effectively bind with high affinity and low energy values to the HIV-1 RT enzyme. The relative binding free energies of Rosmarinic acid, Evafirenz, Arctigenin, Luteolin, Anolignan A, and Quercetin were -66.85, -66.53, -51.83, -49.77, -58.17, and -49.62 Δg bind, respectively. The ADMET profile of Arctigenin was similar to that of Efavirenz, and better than that of other top compounds. The molecular dynamics simulation study showed better stability of rosmarinic acid with the active site of HIV-1 NNRT than the cocrystalized ligand. Out of the top five compounds identified in this study, Rosmarinic acid, a current inhibitor of HIV-1 RT in vitro, showed the most promising prediction. However, further in vivo studies and human clinical trials are required to provide more concrete information regarding its efficacy as potent HIV-1 RT inhibitors.
- 12 November 2025
- Published by Oxford University Press (OUP) in Biology Methods and Protocols
- Vol. 10 (1)
Open AccessIn-silico Identification of Phytochemical Compounds from Various Medicinal Plants as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors Utilizing Molecular Docking and Molecular Dynamics Simulations
HIV is a global public health challenge. The Reverse Transcriptase (RT) enzyme facilitates an important step in HIV replication. Inhibition of this enzyme provides a critical target for HIV treatment. The aim of this study is to employ computational techniques to screen bioactive compounds from different medicinal plants towards identifying potent HIV-1 RT inhibitors better activity than the current ones. We conducted a literature review of HIV-1 RT inhibitors, and eighty-four (84) compounds, while target receptor (1REV) was retrieved from Protein Data Bank. The molecular docking and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) evaluations were performed using the Maestro Schrodinger software user interface. The drug-likeness and pharmacokinetic profile evaluation were carried out using SwissADME and ADMETlab3.0 web servers. Lastly, molecular dynamics simulation study was conducted using the Desmond tool of Schrodinger. The molecular docking study revealed that Rosmarinic acid (-13.265 kcal/mol), Evafirenz/standard drug (-12.175 kcal/mol), Arctigenin (-11.322 kcal/mol), Luteolin (-11.274 kcal/mol), Anolignan A (-11.157 kcal/mol) and Quercetin (-11.129 kcal/mol) can effectively bind with high affinity and low energy values to the HIV-1 RT enzyme. The relative binding free energies of Rosmarinic acid, Evafirenz, Arctigenin, Luteolin, Anolignan A, and Quercetin were -66.85, -66.53, -51.83, -49.77, -58.17, and -49.62 Δg bind, respectively. The ADMET profile of Arctigenin was similar to that of Efavirenz, and better than that of other top compounds. The molecular dynamics simulation study showed better stability of rosmarinic acid with the active site of HIV-1 NNRT than the cocrystalized ligand. Out of the top five compounds identified in this study, Rosmarinic acid, a current inhibitor of HIV-1 RT in vitro, showed the most promising prediction. However, further in vivo studies and human clinical trials are required to provide more concrete information regarding its efficacy as potent HIV-1 RT inhibitors.
- Open Access
- 17 April 2025
- Published by IPS Intelligentsia Publishing Services in Journal of Current Biomedical Research
- Vol. 5 (2, March-A) , 2038-2065
Phytochemical compounds with HIV-1 reverse transcriptase inhibition activity – A review
HIV/AIDS is a global public health issue, exacerbated by the inaccessibility of combination antiretroviral therapy (cART) in some regions. In such settings, herbal therapy can serve as affordable and effective alternative treatment option. Numerous scientific studies have affirmed the inhibitory effects of medicinal plants on several targets in the HIV life cycle, including the HIV type-1 reverse transcriptase (HIV-1 RT) enzyme. To obtain relevant information on the HIV-1 RT inhibition profiles of these medicinal plants, we conducted a literature search for peer-reviewed papers in various scientific databases including PubMed, Scopus, and Google Scholar on bioactive compounds with HIV-1 RT inhibition. We found 60 different plant species distributed across 24 families and reported their respective geographical distribution, specific parts used, bioactive compounds and HIV-1 RT inhibitory profiles. The family Lamiaceae has the highest number of plants (n=10, 16.7%) with HIV-1 RT inhibitory activity. The classes flavonoids, terpenoids and polyphenolic compounds were found to have the highest number of HIV-1 RT inhibition activity. Herbal therapy is an indispensable treatment option for HIV/AIDS, particularly in many low- and middle-income countries and other resource-constrained settings with limited access to cART.
- 17 April 2025
- Published by IPS Intelligentsia Publishing Services in Journal of Current Biomedical Research
- Vol. 5 (2, March-A) , 2038-2065
Open AccessPhytochemical compounds with HIV-1 reverse transcriptase inhibition activity – A review
HIV/AIDS is a global public health issue, exacerbated by the inaccessibility of combination antiretroviral therapy (cART) in some regions. In such settings, herbal therapy can serve as affordable and effective alternative treatment option. Numerous scientific studies have affirmed the inhibitory effects of medicinal plants on several targets in the HIV life cycle, including the HIV type-1 reverse transcriptase (HIV-1 RT) enzyme. To obtain relevant information on the HIV-1 RT inhibition profiles of these medicinal plants, we conducted a literature search for peer-reviewed papers in various scientific databases including PubMed, Scopus, and Google Scholar on bioactive compounds with HIV-1 RT inhibition. We found 60 different plant species distributed across 24 families and reported their respective geographical distribution, specific parts used, bioactive compounds and HIV-1 RT inhibitory profiles. The family Lamiaceae has the highest number of plants (n=10, 16.7%) with HIV-1 RT inhibitory activity. The classes flavonoids, terpenoids and polyphenolic compounds were found to have the highest number of HIV-1 RT inhibition activity. Herbal therapy is an indispensable treatment option for HIV/AIDS, particularly in many low- and middle-income countries and other resource-constrained settings with limited access to cART.
- 19 December 2024
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 24 (03) , 371-387
Machine Learning-Based Drug Repositioning of Novel Human Aromatase Inhibitors Utilizing Molecular Docking and Molecular Dynamic Simulation
In the continuous search for potential drug-like molecules for diseases, drug repurposing offers a solution by identifying new roles for the existing drugs. For breast cancer, which is the leading cause of death among women, discovering a new drug with fewer side effects can take more than a year, and drug repurposing provides a faster alternative. In this study, we used machine learning (ML) and structure-based screening to evaluate molecules from the ChEMBL library against Human Aromatase, an enzyme that is involved in the conversion of androgens to estrogen. The virtual screening output identified 148 potential compounds. These compounds were further subjected to detailed structure-based virtual screening, followed by assessment of induced fit docking, quantum-based docking and ADMET properties. The top compound, CHEMBL502014 and the co-crystallized ligand (reference) were evaluated through MD simulations for 100 ns. The results indicated that the CHEMBL502014-Aromatase complex demonstrated better conformational stability throughout the simulation compared to the reference ligand. Based on these analyses, we propose CHEMBL502014 and other top compounds with known activities against various proteins as potential candidates for anti-cancer activity against breast cancer. These compounds should be further evaluated using experimental assays to confirm their effectiveness against breast cancer.
- 19 December 2024
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 24 (03) , 371-387
Machine Learning-Based Drug Repositioning of Novel Human Aromatase Inhibitors Utilizing Molecular Docking and Molecular Dynamic Simulation
In the continuous search for potential drug-like molecules for diseases, drug repurposing offers a solution by identifying new roles for the existing drugs. For breast cancer, which is the leading cause of death among women, discovering a new drug with fewer side effects can take more than a year, and drug repurposing provides a faster alternative. In this study, we used machine learning (ML) and structure-based screening to evaluate molecules from the ChEMBL library against Human Aromatase, an enzyme that is involved in the conversion of androgens to estrogen. The virtual screening output identified 148 potential compounds. These compounds were further subjected to detailed structure-based virtual screening, followed by assessment of induced fit docking, quantum-based docking and ADMET properties. The top compound, CHEMBL502014 and the co-crystallized ligand (reference) were evaluated through MD simulations for 100 ns. The results indicated that the CHEMBL502014-Aromatase complex demonstrated better conformational stability throughout the simulation compared to the reference ligand. Based on these analyses, we propose CHEMBL502014 and other top compounds with known activities against various proteins as potential candidates for anti-cancer activity against breast cancer. These compounds should be further evaluated using experimental assays to confirm their effectiveness against breast cancer.